419 related articles for article (PubMed ID: 16198295)
21. Crystal structure of the BMP-2-BRIA ectodomain complex.
Kirsch T; Sebald W; Dreyer MK
Nat Struct Biol; 2000 Jun; 7(6):492-6. PubMed ID: 10881198
[TBL] [Abstract][Full Text] [Related]
22. Expression of activin pathway genes in granulosa cells of dominant and subordinate bovine follicles.
Sisco B; Pfeffer PL
Theriogenology; 2007 Jul; 68(1):29-37. PubMed ID: 17467788
[TBL] [Abstract][Full Text] [Related]
23. Rodent adrenocortical cells display high affinity binding sites and proteins for inhibin A, and express components required for autocrine signalling by activins and bone morphogenetic proteins.
Farnworth PG; Wang Y; Leembruggen P; Ooi GT; Harrison C; Robertson DM; Findlay JK
J Endocrinol; 2006 Mar; 188(3):451-65. PubMed ID: 16522726
[TBL] [Abstract][Full Text] [Related]
24. Activins and inhibins and their signaling.
Vale W; Wiater E; Gray P; Harrison C; Bilezikjian L; Choe S
Ann N Y Acad Sci; 2004 Dec; 1038():142-7. PubMed ID: 15838109
[TBL] [Abstract][Full Text] [Related]
25. Activin and follistatin in rat mammary gland.
Bussmann UA; Lanuza GM; Bussmann LE
Mol Cell Endocrinol; 2004 Jun; 221(1-2):9-19. PubMed ID: 15223128
[TBL] [Abstract][Full Text] [Related]
26. betaA- and betaC-activin, follistatin, activin receptor mRNA and betaC-activin peptide expression during rat liver regeneration.
Gold EJ; Zhang X; Wheatley AM; Mellor SL; Cranfield M; Risbridger GP; Groome NP; Fleming JS
J Mol Endocrinol; 2005 Apr; 34(2):505-15. PubMed ID: 15821113
[TBL] [Abstract][Full Text] [Related]
27. Testing the antagonistic effect of follistatin on BMP family members in ovine granulosa cells.
Pierre A; Pisselet C; Monget P; Monniaux D; Fabre S
Reprod Nutr Dev; 2005; 45(4):419-25. PubMed ID: 16045890
[TBL] [Abstract][Full Text] [Related]
28. Melanoma cells secrete follistatin, an antagonist of activin-mediated growth inhibition.
Stove C; Vanrobaeys F; Devreese B; Van Beeumen J; Mareel M; Bracke M
Oncogene; 2004 Jul; 23(31):5330-9. PubMed ID: 15064726
[TBL] [Abstract][Full Text] [Related]
29. Type I receptor binding of bone morphogenetic protein 6 is dependent on N-glycosylation of the ligand.
Saremba S; Nickel J; Seher A; Kotzsch A; Sebald W; Mueller TD
FEBS J; 2008 Jan; 275(1):172-83. PubMed ID: 18070108
[TBL] [Abstract][Full Text] [Related]
30. Activin-A binds follistatin and type II receptors through overlapping binding sites: generation of mutants with isolated binding activities.
Harrison CA; Chan KL; Robertson DM
Endocrinology; 2006 Jun; 147(6):2744-53. PubMed ID: 16527838
[TBL] [Abstract][Full Text] [Related]
31. The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.
Stamler R; Keutmann HT; Sidis Y; Kattamuri C; Schneyer A; Thompson TB
J Biol Chem; 2008 Nov; 283(47):32831-8. PubMed ID: 18768470
[TBL] [Abstract][Full Text] [Related]
32. Structural and functional evidences for a type 1 TGF-beta sensu stricto receptor in the lophotrochozoan Crassostrea gigas suggest conserved molecular mechanisms controlling mesodermal patterning across bilateria.
Herpin A; Lelong C; Becker T; Rosa FM; Favrel P; Cunningham C
Mech Dev; 2005 May; 122(5):695-705. PubMed ID: 15817226
[TBL] [Abstract][Full Text] [Related]
33. Solution structure and backbone dynamics of the TGFbeta type II receptor extracellular domain.
Deep S; Walker KP; Shu Z; Hinck AP
Biochemistry; 2003 Sep; 42(34):10126-39. PubMed ID: 12939140
[TBL] [Abstract][Full Text] [Related]
34. Inhibin, activin, follistatin, activin receptors and beta-glycan gene expression in the villous tissue of miscarriage patients.
Muttukrishna S; Bearfield C; Johns J; Jauniaux E
Mol Hum Reprod; 2004 Nov; 10(11):793-8. PubMed ID: 15361555
[TBL] [Abstract][Full Text] [Related]
35. The activin-follistatin system in the neonatal ovine uterus.
Hayashi K; Carpenter KD; Gray CA; Spencer TE
Biol Reprod; 2003 Sep; 69(3):843-50. PubMed ID: 12748120
[TBL] [Abstract][Full Text] [Related]
36. Control of pelage hair follicle development and cycling by complex interactions between follistatin and activin.
Nakamura M; Matzuk MM; Gerstmayer B; Bosio A; Lauster R; Miyachi Y; Werner S; Paus R
FASEB J; 2003 Mar; 17(3):497-9. PubMed ID: 12514121
[TBL] [Abstract][Full Text] [Related]
37. An activin-A/C chimera exhibits activin and myostatin antagonistic properties.
Muenster U; Harrison CA; Donaldson C; Vale W; Fischer WH
J Biol Chem; 2005 Nov; 280(44):36626-32. PubMed ID: 16129674
[TBL] [Abstract][Full Text] [Related]
38. Antagonists of activin signaling: mechanisms and potential biological applications.
Harrison CA; Gray PC; Vale WW; Robertson DM
Trends Endocrinol Metab; 2005 Mar; 16(2):73-8. PubMed ID: 15734148
[TBL] [Abstract][Full Text] [Related]
39. Mutagenesis analysis of the membrane-proximal ligand binding site of the TGF-beta receptor type III extracellular domain.
Pepin MC; Beauchemin M; Collins C; Plamondon J; O'Connor-McCourt MD
FEBS Lett; 1995 Dec; 377(3):368-72. PubMed ID: 8549757
[TBL] [Abstract][Full Text] [Related]
40. Crystal structure analysis reveals how the Chordin family member crossveinless 2 blocks BMP-2 receptor binding.
Zhang JL; Qiu LY; Kotzsch A; Weidauer S; Patterson L; Hammerschmidt M; Sebald W; Mueller TD
Dev Cell; 2008 May; 14(5):739-50. PubMed ID: 18477456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
